Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Page 1
Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.
Thornton CS, Caverly LJ, Kalikin LM, Carmody LA, McClellan S, LeBar W, Sanders DB, West NE, Goss CH, Flume PA, Heltshe SL, VanDevanter DR, LiPuma JJ. Thornton CS, et al. Among authors: heltshe sl. Ann Am Thorac Soc. 2024 Apr;21(4):595-603. doi: 10.1513/AnnalsATS.202306-576OC. Ann Am Thorac Soc. 2024. PMID: 37963297 Clinical Trial.
Virus positivity was associated with reduced risk of future PEx (hazard ratio, 0.82; 95% confidence interval, 0.69-0.99; P = 0.034) and longer median time to next PEx (255 d vs. 172 d; P = 0.021) compared with virus negativity.Conclusions: More than one-third of STOP2 participant …
Virus positivity was associated with reduced risk of future PEx (hazard ratio, 0.82; 95% confidence interval, 0.69-0.99; P = 0.034) and long …
Prospective evaluation of nontuberculous mycobacteria disease in cystic fibrosis: The design of the PREDICT study.
Martiniano SL, Caceres SM, Poch K, Rysavy NM, Lovell VK, Armantrout E, Jones M, Anthony M, Keck A, Nichols DP, Vandalfsen JM, Sagel SD, Wagner B, Xie J, Weaver K, Heltshe SL, Daley CL, Davidson RM, Nick JA; Investigators of the Cystic Fibrosis NTM Consortium. Martiniano SL, et al. Among authors: heltshe sl. J Cyst Fibros. 2024 Jan;23(1):50-57. doi: 10.1016/j.jcf.2023.08.007. Epub 2023 Sep 4. J Cyst Fibros. 2024. PMID: 37666709 Free article.
Active participants who have not met these criteria are re-consented every 5 years to enable long-term participation. RESULTS: The primary endpoint will summarize the proportion of participants who meet the NTM-PD diagnosis definition. ...
Active participants who have not met these criteria are re-consented every 5 years to enable long-term participation. RESULTS: The pr …
The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis.
VanDevanter EJ, Heltshe SL, Skalland M, Lechtzin N, Nichols D, Goss CH. VanDevanter EJ, et al. Among authors: heltshe sl. J Cyst Fibros. 2021 Nov;20(6):932-936. doi: 10.1016/j.jcf.2021.02.012. Epub 2021 Mar 5. J Cyst Fibros. 2021. PMID: 33685776 Free PMC article. Clinical Trial.
BACKGROUND: Retrospective studies indicate that more cystic fibrosis (CF) pulmonary exacerbations (PEx) are treated with oral (PO) than with intravenous (IV) antimicrobials despite little knowledge of the relative effects of PO treatment on lung function recovery or long-term …
BACKGROUND: Retrospective studies indicate that more cystic fibrosis (CF) pulmonary exacerbations (PEx) are treated with oral (PO) than with …
Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.
Guimbellot JS, Baines A, Paynter A, Heltshe SL, VanDalfsen J, Jain M, Rowe SM, Sagel SD; GOAL-e2 Investigators. Guimbellot JS, et al. Among authors: heltshe sl. J Cyst Fibros. 2021 Mar;20(2):213-219. doi: 10.1016/j.jcf.2020.11.008. Epub 2020 Nov 25. J Cyst Fibros. 2021. PMID: 33249004 Free PMC article.
BACKGROUND: The cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, ivacaftor, was first approved for people with CF and the G551D CFTR mutation. This study describes the long-term clinical effectiveness of ivacaftor in this population. METHODS: We cond …
BACKGROUND: The cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, ivacaftor, was first approved for people with CF and …
Fecal dysbiosis in infants with cystic fibrosis is associated with early linear growth failure.
Hayden HS, Eng A, Pope CE, Brittnacher MJ, Vo AT, Weiss EJ, Hager KR, Martin BD, Leung DH, Heltshe SL, Borenstein E, Miller SI, Hoffman LR. Hayden HS, et al. Among authors: heltshe sl. Nat Med. 2020 Feb;26(2):215-221. doi: 10.1038/s41591-019-0714-x. Epub 2020 Jan 20. Nat Med. 2020. PMID: 31959989 Free PMC article.
Although this early linear growth failure is associated with worse long-term respiratory function and survival(2,3), the determinants of body length in infants with CF have not been defined. ...
Although this early linear growth failure is associated with worse long-term respiratory function and survival(2,3), the determinants …
Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis.
Nichols DP, Odem-Davis K, Cogen JD, Goss CH, Ren CL, Skalland M, Somayaji R, Heltshe SL. Nichols DP, et al. Among authors: heltshe sl. Am J Respir Crit Care Med. 2020 Feb 15;201(4):430-437. doi: 10.1164/rccm.201906-1206OC. Am J Respir Crit Care Med. 2020. PMID: 31661302 Free PMC article.
Rationale: Chronic azithromycin is commonly used in cystic fibrosis based on short controlled clinical trials showing reductions in pulmonary exacerbations and improved FEV(1). Long-term effects are unknown.Objectives: Examine pulmonary outcomes among chronic azithromycin …
Rationale: Chronic azithromycin is commonly used in cystic fibrosis based on short controlled clinical trials showing reductions in pulmonar …
Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.
Heltshe SL, Goss CH, Thompson V, Sagel SD, Sanders DB, Marshall BC, Flume PA. Heltshe SL, et al. Thorax. 2016 Mar;71(3):223-9. doi: 10.1136/thoraxjnl-2014-206750. Epub 2015 Apr 24. Thorax. 2016. PMID: 25911223 Free PMC article.
To design trials evaluating PEx treatment factors, we characterise the heterogeneity of PEx care in adults and paediatrics, and correlate it with measures of clinical response including short-term and long-term lung function changes, change in symptom severity score …
To design trials evaluating PEx treatment factors, we characterise the heterogeneity of PEx care in adults and paediatrics, and correlate it …
Using multiple imputation to assign pesticide use for non-responders in the follow-up questionnaire in the Agricultural Health Study.
Heltshe SL, Lubin JH, Koutros S, Coble JB, Ji BT, Alavanja MC, Blair A, Sandler DP, Hines CJ, Thomas KW, Barker J, Andreotti G, Hoppin JA, Beane Freeman LE. Heltshe SL, et al. J Expo Sci Environ Epidemiol. 2012 Jul;22(4):409-16. doi: 10.1038/jes.2012.31. Epub 2012 May 9. J Expo Sci Environ Epidemiol. 2012. PMID: 22569205 Free PMC article.
Missing pesticide use information from participants who did not complete the second questionnaire impedes both long-term pesticide exposure estimation and statistical inference of risk for health outcomes. ...
Missing pesticide use information from participants who did not complete the second questionnaire impedes both long-term pesticide ex …
Assets and liabilities of the Burn Model System data model: a comparison with the National Burn Registry.
Lezotte DC, Hills RA, Heltshe SL, Holavanahalli RK, Fauerbach JA, Blakeney P, Klein MB, Engrav LH. Lezotte DC, et al. Among authors: heltshe sl. Arch Phys Med Rehabil. 2007 Dec;88(12 Suppl 2):S7-17. doi: 10.1016/j.apmr.2007.09.011. Arch Phys Med Rehabil. 2007. PMID: 18036984
RESULTS: Although minor deviations in demographic distributions were found between the BMS and NBR and between discharge and follow-up populations, our results show that the BMS population sample is internally and externally valid and is adequate for answering research questions. …
RESULTS: Although minor deviations in demographic distributions were found between the BMS and NBR and between discharge and follow-up popul …
11 results